Cytokine and Eicosanoid Mediators in Coronavirus Disease 2019 (COVID-19)
NCT04452942 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 30
Last updated 2020-07-21
Summary
This study is a prospective, single center, observational, cohort study of patients to (1) describe the kinetics and temporal relationship of changes in eicosanoid and cytokine mediators in patients with severe COVID-19 admitted to the hospital; and (2) correlate the dynamic changes in eicosanoid mediators with available patient clinical status, including measures of severity of illness, routine laboratory tests, and outcomes.
Conditions
Sponsors & Collaborators
-
EicOsis Human Health Inc.
lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-07-31
- Primary Completion
- 2020-09-30
- Completion
- 2021-04-30
Countries
- United States
Study Locations
More Related Trials
-
Efficacy and Safety of Corticosteroids in COVID-19
NCT04273321 ·Status: COMPLETED ·Phase: NA
-
Dynamics of Markers of Infection and Inflammation in Hospitalized Coronavirus Disease 2019 (COVID-19) Patients
NCT04887623 ·Status: RECRUITING
-
Assesment of the Metabolomic Signature in COVID-19 Patients
NCT04497272 ·Status: COMPLETED ·Phase: NA
-
Recovery of Respiratory System in COVID-19 Patients
NCT04954222 ·Status: COMPLETED
-
Association of the Neutrophil/Lymphocyte Ratio With Pulmonary Complications and Mortality in COVID-19 Patients
NCT05052346 ·Status: COMPLETED
-
Cyclosporine A Plus Low-steroid Treatment in COVID-19 Pneumonia
NCT04540926 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
A Retrospective Study of COVID-19 Treatments
NCT04949230 ·Status: COMPLETED
-
Clinical Progressive Characteristics and Treatment Effects of 2019-novel Coronavirus
NCT04292327 ·Status: UNKNOWN
-
COVID-EC Study: Clinical Characteristics of Patients With COVID-19 in Guayaquil, Ecuador
NCT04362969 ·Status: UNKNOWN
-
Place of Circulating Biomarkers and Respiratory Eicosanoids in the Prognosis of Severe Forms of Covid-19 Pneumonia
NCT04485364 ·Status: COMPLETED
-
Early Treatment Strategy With High-dose Dexamethasone in Patients With SARS-CoV-2
NCT05293210 ·Status: UNKNOWN ·Phase: PHASE3
-
Tofacitinib in Hospitalized Patients With COVID-19 Pneumonia
NCT04469114 ·Status: COMPLETED ·Phase: PHASE3
-
Corona Virus Disease 2019 Patients Whose Nucleic Acids Changed From Negative to Positive
NCT04333589 ·Status: UNKNOWN ·Phase: NA
-
Assessment of Lung Inflammation With FDG PET/CT in COVID-19
NCT04441489 ·Status: COMPLETED
-
Colchicine Counteracting Inflammation in COVID-19 Pneumonia
NCT04322565 ·Status: COMPLETED ·Phase: PHASE2
-
The Natural History of Hospitalized COVID-19 Patients
NCT04424992 ·Status: RECRUITING
-
Prophylactic Corticosteroid to Prevent COVID-19 Cytokine Storm
NCT04355247 ·Status: UNKNOWN ·Phase: PHASE2
-
Diagnostic Study of Biomarkers in BAL of ICU Patients With Lung Infiltrates
NCT01695499 ·Status: UNKNOWN
-
Health Professional Exposure Assessment to Covid-19
NCT04429724 ·Status: COMPLETED ·Phase: NA
-
Association of the Neutrophil/Lymphocyte Ratio With Clinical Complications and Mortality in COVID-19 Patients
NCT04434157 ·Status: COMPLETED
-
How Routine Biomarkers and Blood Leucocytes Count Can Assist Diagnosis of COVID-19 in Emergency Department
NCT04401241 ·Status: COMPLETED
-
The Efficacy of Different Hormone Doses in 2019-nCoV Severe Pneumonia
NCT04263402 ·Status: UNKNOWN ·Phase: PHASE4
-
Study to Evaluate the Efficacy and Safety of Tocilizumab Versus Corticosteroids in Hospitalised COVID-19 Patients With High Risk of Progression
NCT04345445 ·Status: UNKNOWN ·Phase: PHASE3
-
An Observational Study of Patients With Coronavirus Disease 2019
NCT04331886 ·Status: COMPLETED
-
IL-12RB and TNF-alpha Gene Polymorphism and Susceptibility and Progress of Covid-19 SARS-CoV-2: A Case Control Study
NCT04462120 ·Status: UNKNOWN